Disease flares during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia

被引：0
|
作者：
Hampel, Paul [1 ]
Call, Timothy [2 ]
Rabe, Kari [2 ]
Ding, Wei [2 ]
Muchtar, Eli [2 ]
Kenderian, Saad [2 ]
Leis, Jose [2 ]
Witzig, Thomas [2 ]
Koehler, Amber [2 ]
Fonder, Amie [2 ]
Schwager, Susan [2 ]
Van Dyke, Daniel [2 ]
Slager, Susan [2 ]
Kay, Neil [2 ]
Parikh, Sameer [2 ]
机构：
[1] Mayo Clin, Sch Grad Med Educ, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
来源：
LEUKEMIA & LYMPHOMA | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2117
引用
收藏
页码：204 / 206
页数：3
相关论文
共 50 条
  • [41] Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1440): : 29 - 30
  • [42] Ibrutinib for Chronic Lymphocytic Leukemia REPLY
    Burger, Jan A.
    Styles, Lori
    Kipps, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (16): : 1594 - 1595
  • [43] Ibrutinib Resistance in Chronic Lymphocytic Leukemia
    Furman, Richard R.
    Cheng, Shuhua
    Lu, Pin
    Setty, Menu
    Perez, Alexendar R.
    Guo, Ailin
    Racchumi, Joelle
    Xu, Guozhou
    Wu, Hao
    Ma, Jiao
    Steggerda, Susanne M.
    Coleman, Morton
    Leslie, Christina
    Wang, Y. Lynn
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2352 - 2354
  • [44] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Farooqui, Mohammed Z. H.
    Wiestner, Adrian
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 925 - 933
  • [45] The Use of Ibrutinib in Chronic Lymphocytic Leukemia
    Damon, Lloyd E.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 154 - 156
  • [46] Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.
    Hampel, Paul Joseph
    Chaffee, Kari G.
    Ding, Wei
    Call, Timothy
    Kenderian, Saad
    Muchtar, Eli
    Leis, Jose Francisco
    Chanan-Khan, Asher Alban Akmal
    Bowen, Deborah
    Fonder, Amie L.
    Schwager, Susan M.
    Slager, Susan L.
    Shanafelt, Tait D.
    Kay, Neil E.
    Parikh, Sameer Ashok
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 13 - 14
  • [48] Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
    Jain, Preetesh
    Keating, Michael
    Wierda, William
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    George, Binsah
    James, Danelle
    Kantarjian, Hagop
    Burger, Jan
    O'Brien, Susan
    BLOOD, 2015, 125 (13) : 2062 - 2067
  • [49] Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia
    Cao, Zhijian
    Ma, Jun
    BLOOD, 2019, 134
  • [50] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
12345